Arcutis Biotherapeutics (ARQT)

• Market cap: $3.49B
• 1 day: -3.22%
• 5 days: -9.17%
• 1 month: 21.62%
• 3 months: 64.95%
• 6 months: 111.26%
• Year to date: 95.88%
• 1 year: 132.82%
• 5 years: -2.19%
• 10 years: 30.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Employees: 342